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cTnI (57% vs 80%, respectively; log-rank chi-squared 28.0
and P < .0001; Figure 3A).
Grouped by hs-cTnT level, hs-cTnT tertiles 1, 2, and 3
had 29, 55, and 86 deaths, respectively, with significant
decrements in survival for increasing tertiles (Figure 3B,
log-rank chi-squared 44.9 and P < .0001). Increased
hs-cTnT was associated with nearly a 3.7-fold increase in
5-year mortality (tertile 1 vs 3, HR 3.74; 95% CI, 2.49-5.79;
P < .0001). After adjustment for traditional risk factors
in addition to hypertension history, and coronary artery
disease history, eGFR, NT-proBNP, angiotensin-converting
enzyme inhibitor/angiotensin receptor blocker use, beta-
blocker use, history of chronic obstructive pulmonary dis-
ease, serum sodium, left ventricular ejection fraction, and
blood urea nitrogen, increased hs-cTnT remained indepen-
dently associated with 5-year mortality (tertile 1 vs 3, HR
2.14; 95% CI, 1.24-3.79, P ¼ .006).
In comparison with the base model for mortality with
cTnI, the prognostic accuracy of the model with hs-cTnT
(Table 2) was improved modestly (AUC 66.1% and AUC
69.4%, respectively, P ¼ .03) with a 9.0% IDI (P < .001)
and 13.6% NRI (P < .001). In contrast, there was no
increase in prognostic accuracy when cTnI and hs-cTnT
were both added to the base model for mortality (AUC
69.4% and AUC 69.2%, respectively, P ¼ .9), although
there was continued IDI (9.0%, P < .001) and NRI (3.6%,
P < .001).
Circulating hs-cTnT and Mortality in the
Detectable cTnI Subgroup
In the subgroup with detectable cTnI (n ¼ 302), cTnI and
hs-cTnT were correlated (Spearman’s rho 0.74, P < .0001).
The highest hs-cTnT tertile was associated with a 2.1-fold
increase in 5-year mortality risk when compared with the
lowest hs-cTnT tertile (HR 2.1; 95% CI, 1.4-3.3; P ¼ .0009,
Figure 4). After multivariate adjustment for traditional risk
factors, the association between high hs-cTnT and mortality
persisted (HR 2.0; 95% CI, 1.3-3.2; P ¼ .003). In a sensi-
tivity analysis with additional adjustment for hypertension
history and coronary artery disease history, the association
between high hs-cTnT and mortality persisted (HR 1.96;
95% CI, 1.22-3.20, P ¼ .005). In further sensitivity analyses
with additional adjustment for eGFR to traditional risk
factors, there was a similar association with high hs-cTnT
and mortality (HR 2.1; 95% CI, 1.1-4.0; P ¼ .03), but the
effects were not significant when NT-proBNP was further
added to the model.
In comparison with the base model for mortality with
cTnI (AUC 70.8%), the prognostic accuracy of base model
with hs-cTnT or with both hs-cTnT and cTnI was not
different (AUC 71.2%, P ¼ .8 and AUC 70.9%, P ¼ .9;
respectively; Table 2). However, both models had sustained
IDI at 11.0% (P < .001, for both) and had 8.1%
(P < .001) and 6.8% (P < .001) event-specific NRI,
Figure 3 (A) Kaplan Meier estimates of 5 year survival rates according to cTnI levels above or below the limit of detection (n ¼ 504).
P value calculated by the log rank test. (B) Kaplan Meier estimates of 5 year survival rates according to hs cTnT levels (n ¼ 504). P
value calculated by the log rank test. cTnI ¼ cardiac troponin I; hs cTnT ¼ high sensitivity cardiac troponin T.
Figure 2 Cardiac troponin levels stratified by left ventricular
ejection fraction. P value calculated by Wilcoxon test. LVEF ¼
left ventricular ejection fraction; cTnI ¼ cardiac troponin I; hs
cTnT ¼ high sensitivity cardiac troponin T.

eGFR. However, while the analytical performance of hs-
cTnT appeared superior, there was overlap in prognostic
accuracy of hs-cTnT in subjects with detectable cTnI. These
findings highlight the prognostic value of highly sensitive
cTn assays in the setting of heart failure, yet also point to the
need for future studies to better determine whether the
improved sensitivity of cTn assays can translate into incre-
mental clinical benefits.
In contrast to the general population,15,16 patients with
chronic heart failure have more prevalent detectable cTn. The
etiology of cTn release in chronic heart failure patients
is unclear and likely multifactorial. It may be triggered by
acute and chronic myocardial stress, chronic sub-clinical
sub-endocardial ischemia, or direct cardiomyocyte injury.17
It also may result from increased apoptosis in heart failure,5
thus representing increased cardiomyocyte turnover, which
may be indicative of progressive myocardial dysfunction.
In heart failure patients, circulating cTn levels have prog-
nostic value independent of renal function18 and natriuretic
peptide levels,19 in heart failure with either reduced or pre-
served left ventricular ejection fraction,20 and in the elderly.11
Our results support and add to the growing body of
evidence that detectable cTn at any level of assay sensi-
tivity has strong prognostic utility in patients with heart
failure.7-11,21-23 As hypothesized, increased circulating hs-
cTnT was independently and incrementally associated with
incident 5-year mortality after multivariate adjustment for
strong heart failure risk factors. Previously, a retrospective
analysis of the Valsartan Heart Failure Trial (Val-HeFT)
found a similarly high portion (92.0%; 3728/4053) had
detectable hs-cTn by an older assay.7 In this and another
analysis that pooled the Val-HeFT and Gruppo Italiano per
lo Studio della Sproavvivenza nell’Insufficienza Cardiaca-
Heart Failure cohorts,9 higher circulating hs-cTn was asso-
ciated with both incident heart failure hospitalization and
mortality, and improved the prognostic accuracy of subjects’
clinical risk factors in addition to B-type natriuretic peptide.
Unlike our analysis, however, no head-to-head comparisons
were made between circulating cTn by both assays.
What is unclear from previous chronic heart failure
cohorts, where circulating cTn is measured by both as-
says,7,9 is determining whether there is a clinical advantage
to prognosticate by measuring hs-cTn when cTn may be
detectable by a standard assay; and if such an advantage is
related to the increased sensitivity of the hs-cTn assay. In
our cohort, circulating hs-cTnT had higher prognostic
accuracy when compared with circulating cTnI, thus
supporting the use of measuring cTn by high-sensitivity
assays instead of standard assays in chronic heart failure.
However, there was overlap in incident mortality discrimi-
nation of measuring circulating hs-cTnT if cTnI was
detectable, which questions the use of measuring cTn by a
high-sensitivity assay if cTn is in the detectable range of the
standard assay. Therefore, these results suggest that circu-
lating hs-cTn may have a higher prognostic accuracy
primarily as a result of their increased sensitivity.6 In other
words, when patients present with a quantifiable cTn level
based on standard assay, there appears to be an incremental
benefit to stratify risk, although a limited change in endpoint
prediction (discrimination) with the addition of a highly
sensitive cTn test based on our findings. Risk calibration and
endpoint discrimination are often discordant for major
disease factors, and excessive reliance on the AUC has been
discouraged previously.24
One of the biggest advantages of utilizing a more sensitive
assay is to expand the lower range of quantifiable cTn. From
head-to-head comparisons in non-heart-failure populations,
circulating cTn measured by high-sensitivity assays identifies
a larger population with cardiac risk factors, structural cardiac
abnormalities, increased risk of incident heart failure, and
adverse cardiac events than circulating cTn measured by
standard assays.15,16,25 In the undetectable cTnI subgroup,
very low levels of circulating hs-cTnT were still associated
with 5-year mortality (Figure 4). This suggests that very low
circulating hs-cTnT, well below the assay’s 99th percentile
cut-off, yields prognostically important information in
patients with heart failure and are supported by similar
findings in previous heart failure cohorts.7,9,11 Taken in
aggregate, there appears to be clinically important informa-
tion embedded in very low cTn levels, thus questioning the
clinical utility of using a 99th percentile cut-off for “normal”
in patients with heart failure. Although we describe associa-
tions of very low cTn levels with age, NT-proBNP, and renal
function, further studies are needed to determine the etiology
of cTn release and whether similarly low-risk chronic heart
failure populations need further risk stratification.
Furthermore, high-sensitivity cTn levels may be viable
therapeutic targets for medication titration in similarly
low-risk patients with chronic heart failure. In patients with
non-ST-segment elevation acute coronary syndromes, anti-
platelet therapy escalation guided by circulating cTn has
been shown to favorably influence treatment outcomes.26
Indeed, detectable cTn levels in the setting of receiving
high-dose chemotherapy have already demonstrated the
ability to identify a patient population with risk of
progressive deterioration of cardiac dysfunction that may
be ameliorated by initiation of angiotensin-converting
enzyme inhibitors.27 In heart failure, however, whether
adjusting chronic heart failure therapy (beta-blockers, renin-
angiotensin blockers, or mineralocorticoid receptor antago-
nists) affects serial hs-cTn levels is unknown. Yet, because
changing high-sensitivity cTn levels are associated with
prognosis in chronic heart failure,9,28 future studies to assess
associations of medical therapy adjustments and changes in
high-sensitivity cTn levels are therefore warranted.
These results must be interpreted in the context of several
limitations in our study design. Because cTn levels were
measured at only one point in time, we were unable to
examine the variability and prognostic value of changing
cTn levels by 2 cTn assays over time or the impact of
different therapies in the interim. We cannot exclude the
presence of selection bias for those undergoing coronary
angiography for further evaluation and management of heart
failure at a tertiary care center, even though based on
baseline clinical characteristics, our cohort is relatively
representative of a contemporary patient population with
chronic heart failure with both preserved and reduced left
ventricular ejection fraction, and we excluded all patients
with any suspicion or clinical history of acute coronary
syndromes. However, limitations to external validity include
a large proportion of patients in this analysis with ischemic
cardiomyopathy. Indeed, many noncardiac conditions are
associated with detectable circulating troponin,29 such as
sepsis, pulmonary embolism, chronic kidney disease, and
myocarditis. With the exception of renal dysfunction, the
incidence of these and other acute conditions where troponin
is associated with mortality was likely very low as subjects
in this study were included before elective coronary angi-
ography. Nevertheless, based on these analyses and because
we are in the era when recognizing the potential harms
for excessive diagnostics are at the forefront, further
investigations continuing to clarify clinical utilities of cTn
measured by highly sensitive assays are warranted.
CONCLUSION
In patients with chronic heart failure, when compared with
standard assays, high-sensitivity assays identify more pa-
tients with detectable circulating cTn. Although plasma
hs-cTnT levels provide incremental and independent prog-
nostic value and increased prognostic accuracy in patients
with chronic heart failure, there is overlap in this value when
both assays measure cTn in the detectable range.
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